News | Biopsy Systems | March 16, 2017

Exact Imaging Announces Health Canada Approval and License for ExactVu Micro-Ultrasound System

First Canadian customer will use prostate biopsy system in study to better understand apoptosis and how cancerous cells respond to therapy

Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota

March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#98667) to sell its ExactVu high resolution micro-ultrasound biopsy system in Canada. The first device was sold to Gregory Czarnota, M.D., and Sunnybrook Health Sciences Centre and Sunnybrook Research Institute in Toronto.

"The unmatched resolution of the ExactVu micro-ultrasound system will provide important capabilities to our urologists in helping them actually visualize and distinguish suspicious tissue — and therefore allows us to actually target our prostate biopsies," said Czarnota, director of the Odette Cancer Research Program, Sunnybrook Research Institute and Radiation Oncologist at Sunnybrook Health Sciences Centre. "Furthermore, the ExactVu's high resolution imaging also generates rich RF (or radiofrequency) data which our research teams can evaluate and correlate with pathology to apply against our models to better understand apoptosis and how cancerous cells respond to therapy. We see very exciting potential in the ExactVu system and look forward to our collaboration with the team at Exact Imaging."

Czarnota discovered that high-frequency ultrasound could be used to detect apoptosis or cell death. This finding has since been applied to important questions in oncology and organ transplantation. Czarnota's research group is investigating a number of spectroscopic parameters for characterizing tumors and tumor responses to chemotherapy and radiation therapy at high frequencies and intends to use the ExactVu for such purposes. Specific applications include developing methods to generate color-coded ultrasound parametric maps to aid in assessing tumor responses to therapy. Since these spectroscopic signals are potentially linked to nuclear structure and chromatin structure that differs between normal and neoplastic tissue, there is potential to develop our spectroscopic methods not only into a method to track tumor responses but a potentially important diagnostic tool.

For more information: www.exactimaging.com

Related Content

Toshiba, Aplio i-series, MSK, musculoskeletal ultrasound, RSNA 2017
Technology | Ultrasound Imaging | March 29, 2017
March 29, 2017 — Toshiba Medical recently announced the launch of its new premium Aplio i-series...
high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017
EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity...
prenatal ultrasound, decreased bone density, rabbit study, Pertanika Journal of Science & Technology
News | Ultrasound Imaging | March 28, 2017
March 28, 2017 — Young rabbits exposed to...
VERT, virtual environment radiotherapy, radiation therapy, patient anxiety, Thomas Jefferson University study
News | Radiation Therapy | March 27, 2017
March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation treatmen
ContextVision, 3-D ultrasound, SkeletalView, patent, fetal skeleton viewing, RSNA 2017
News | Advanced Visualization | March 23, 2017
ContextVision recently received a patent approval on a new skeletal visualization technology for 3-D ultrasound.
Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017
March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the UroN
News | Prostate Cancer | March 22, 2017
Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to...
Carestream, Touch Prime ultrasound systems, AIUM 2017 convention, American Institute of Ultrasound in Medicine, RSNA 2017
News | Ultrasound Imaging | March 22, 2017
Carestream Health will show its Carestream Touch Prime and Touch Prime XE Ultrasound Systems at the American Institute...
Toshiba Medical, Aplio i900 cardiovascular ultrasound, FDA clearance, ACC 2017, RSNA 2017
Technology | Cardiovascular Ultrasound | March 20, 2017
March 20, 2017 — Cardiologists can now access the advanced...
PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017
The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates...
Overlay Init